Wall Street analysts expect ADMA Biologics Inc (NASDAQ:ADMA) to report $4.36 million in sales for the current fiscal quarter, Zacks Investment Research reports. Five analysts have made estimates for ADMA Biologics’ earnings. The lowest sales estimate is $2.50 million and the highest is $9.21 million. ADMA Biologics reported sales of $4.66 million during the same quarter last year, which indicates a negative year over year growth rate of 6.4%. The company is expected to issue its next earnings report on Friday, August 9th.
On average, analysts expect that ADMA Biologics will report full-year sales of $24.30 million for the current year, with estimates ranging from $18.80 million to $43.91 million. For the next fiscal year, analysts expect that the business will post sales of $59.92 million, with estimates ranging from $49.10 million to $82.19 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover ADMA Biologics.
ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($0.31) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.32) by $0.01. The firm had revenue of $3.53 million for the quarter, compared to analysts’ expectations of $2.96 million. ADMA Biologics had a negative net margin of 370.27% and a negative return on equity of 210.69%.
ADMA has been the topic of several research analyst reports. Oppenheimer set a $14.00 price target on shares of ADMA Biologics and gave the company a “buy” rating in a report on Tuesday, June 25th. HC Wainwright set a $7.00 target price on shares of Armata Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, May 23rd. Jefferies Financial Group assumed coverage on shares of ADMA Biologics in a research note on Tuesday, June 4th. They set a “buy” rating and a $8.00 target price for the company. ValuEngine raised shares of Yelp from a “sell” rating to a “hold” rating in a research note on Wednesday, April 3rd. Finally, Maxim Group set a $8.00 price target on shares of TrovaGene and gave the company a “buy” rating in a research note on Tuesday, April 2nd. Nine analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and a consensus price target of $11.17.
In related news, major shareholder Life Sciences Maste Perceptive acquired 4,000,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 21st. The stock was purchased at an average price of $4.00 per share, for a total transaction of $16,000,000.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Adam S. Grossman acquired 30,000 shares of the company’s stock in a transaction that occurred on Friday, May 17th. The stock was bought at an average price of $4.00 per share, with a total value of $120,000.00. Following the transaction, the insider now directly owns 37,527 shares in the company, valued at $150,108. The disclosure for this purchase can be found here. In the last three months, insiders bought 4,064,500 shares of company stock worth $16,258,000. Insiders own 18.80% of the company’s stock.
Several institutional investors have recently modified their holdings of ADMA. Burns J W & Co. Inc. NY acquired a new position in ADMA Biologics during the first quarter worth $55,000. Diag Capital Management LP purchased a new position in ADMA Biologics in the fourth quarter valued at about $435,000. Geode Capital Management LLC boosted its holdings in ADMA Biologics by 14.4% in the fourth quarter. Geode Capital Management LLC now owns 276,930 shares of the biotechnology company’s stock valued at $661,000 after purchasing an additional 34,818 shares during the last quarter. Dimensional Fund Advisors LP purchased a new position in ADMA Biologics in the fourth quarter valued at about $34,000. Finally, United Services Automobile Association purchased a new position in ADMA Biologics in the fourth quarter valued at about $27,000. Institutional investors own 38.70% of the company’s stock.
ADMA Biologics stock remained flat at $$3.89 during trading hours on Friday. 554,289 shares of the company’s stock traded hands, compared to its average volume of 691,734. The company has a market cap of $224.08 million, a PE ratio of -2.68 and a beta of 2.71. The company has a debt-to-equity ratio of 5.70, a current ratio of 4.60 and a quick ratio of 2.39. ADMA Biologics has a 52-week low of $2.08 and a 52-week high of $6.96. The business’s 50 day moving average is $3.84.
About ADMA Biologics
ADMA Biologics, Inc, a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.
See Also: How does a margin account work?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.